Press Clippings

Press release at The Hindu, 21.06.2011, Chennai By Special Corresponden

The Hindu, 21.06.2011, Chennai – K.P.Mundhra Executive Director, Albert David said the company’s formulations, Placentrex(gel and injection) is the only human placenta based product in the country developed through indigenous research. He added that not a single negative adverse drug reaction or side effect had been noted in the 60 years of the use of the injection and 11 years’ use of the gel. The placentas are collected from multiple city hospitals in Kolkata, thanks to a special arrangement with the State’s Health and Family Welfare Ministry. About 300 placenta are collected every single day, refrigerated, transported to the factory, where they are stored for seven days after which the process of extraction begins. During the processing, the product is tested at three stages for harbouring viruses or bacteria. “ At the temperature we use as part of our patented process, it is impossible for these organisms to survive,” he said.

 

Press release at The Times of India 21.06.2011, Chennai By Times News Network

The Times of India, 21.06.2011, Chennai – “We proved that the placenta we used were safe and tested. There are no side effects to this drug and there are no alternatives. Antibiotics can cure infections but can not treat inflammations. Doctors have trusted our drug. Said K.P.Mundhra, Executive Director of Albert David, which manufactures Placentrex. The cost of the injection is Rs.41 per ampoule, and Rs.50 for a tube of gel. For treatment of Pelvic inflammations a woman would need 15 ampoules.

 

 

 

Albert David to set up unit with R&D facility The Economic Times dated 18.1.2000, Sutapa Raha,Kolkata, 17th January

Keeping the heady days of the post-TRIPS era and product patent regime in mind, drug manufacturers back home are slowly drawing up strategies for survival and good health.

A case in point is the decades old Kolkata-headquartered, Albert David Ltd, which is not only setting up a new manufacturing unit bundled with an R&D facility but is also eyeing licensing agreements with pharmaceutical companies abroad.

K.P. Mundra, Executive Editor of Albert David Ltd., told ET : "With more and more MNCs entering the pharmaceutical market in India, we need to have state-of-the-art technologies for production of quality products and thereby meet competition head-on. Our R&D facility will also have to be strengthened."

To begin with, Albert David is setting up a new factory in Kolkata with an investment of Rs 40 crore. The unit will club the company´s R&D centre, for advanced research on formulations. Investment will be in phases and the project will be partly funded by the company's own earnings and partly by different FIs.

Speaking about the new project, Mr. Mundhra said: "We already manufacture a wide range of formulations, large volume parentals and medical disposables. Now the IV fluid market is very competitive and the market is only growing by 8-10 percent a year. Therefore, we would concentrate on the formulations market."

"This new facility would manufacture oral liquids, tablets, ointments and some bulk drugs. Our aim is to increase our present production and launch more and more new products every year. With a strong R&D we hope to do that," he added.

The company is also looking at some licensing tie-ups with foreign pharma companies who have not yet entered the Indian market.
Albert David to set up a new mfg facility at Kolkata, Pharmacon dated 24.02.2000

The new facility, which would commence operations tentatively by 2002, would manufacture oral liquids, tablets, ointments and some bulk drugs. "The aim is to increase the present production and launch more and more new products every year and with a strong R&D team we hope to achieve it," Mundhra added.

Joy Roy Choudhury,Kolkata

In the post-TRIPs era Indian drug manufacturers are realigning their survival strategies. With more and more MNCs entering the domestic market and keeping the product patent regime ahead, domestic manufacturers are drawing up strategies for their sustainable growth and survival.

The decades old Kolkata-based Albert David Ltd., a leading and fast growing professionally managed pharmaceutical company is setting up a new manufacturing facility along with an advanced R&D facility as a part of its modernisation and upgradation plans.

The company is also in the final stages of negotiations with foreign pharma companies for licensing agreements.

K.P. Mundhra, executive director of Albert David Ltd. in an exclusive interview to Express Pharma Pulse said. "As more and more MNCs are entering the pharma market in India we cannot afford to sit idle. We need to upgrade our manufacturing facilities and have state-of-the-art technologies for production of quality products so that we can meet the challenges posed by the MNCs. So for these our R&D facility will also have to be strengthened."

The company will be finalising the exact location of the new factory to be set up in Kolkata within two months. The cost of the entire project has been pegged at Rs 40 crore. The investment will be in phases now and the project will be partly funded by the company's own earnings and partly by different FIs.

Albert David has multi-centric manufacturing plants located in Kolkata, Ghaziabad and Mandideep near Bhopal (MP). The manufacturing units of the company have been accorded WHOGMP accreditation. The bulk drug manufacturing facility has been approved by US FDA.

Albert David ranked 58th out of 16,000 plus pharma companies is a part of the Kothari Group of companies.

"We manufacture and market a wide range of formulations, large volume parenterals and medical disposables. We would concentrate on the formulations market," Mundhra informed.

Some of the products are regularly exported to different countries including the United States and Europe. At present the company is operating in major therapeutic segments, herbal drugs, anti-bacterials, nutrition, anti-ulcerants, neurotropics, placental extracts, anxiolytics, small and large volume parenterals, dermatologicals and disposable syringes and needles. Albert David is a leader in human placental extract therapy.
Albert David to set up a new mfg facility at Kolkata, Express Pharma Pulse dated 27.1.2000

As more and more MNCs are entering the Indian pharmaceuticals market we cannot afford to sit idle. We need to upgrade our manufacturing facilities and have state-of-art technologies for the production of quality products so that we can meet the challenges posed by MNCs.

EPP Team Kolkata

In the post-TRIPS era, Indian drug manufacturers are realigning their survival strategies. With more and more MNCs entering the domestic market and keeping the product patent regime ahead, domestic manufacturers are drawing up strategies for their sustainable growth and survival.

Kolkata-based Albert David Ltd. a leading and fast growing professionally managed pharmaceutical company is setting up a new manufacturing facility along with an advanced R&D facility as a part of its modernization and upgradation plans.

The company is also in the final stages of negotiations with foreign pharma companies for licensing agreements. "As many more MNCs are entering the Indian pharmaceuticals market we cannot afford to sit idle. We need to upgrade our manufacturing facilities and have state-of-art technologies for the production of quality products so that we can meet the challenges posed by MNCs. So, for these, our R&D facility will also have to be strengthened," said K.P. Mundhra, Executive Director, Albert David.

The company will be finalizing the exact location of the new factory to be set up at Kolkata soon. The cost of the project estimated at Rs 40 crore, will be funded by the company's own earnings and partly by different financial institutions. Albert David has multicentric manufacturing plants located in Kolkata, Ghaziabad and Mandideep near Bhopal in Madhya Pradesh. The manufacturing units of the company have been accorded WHO-GMP accredition. The bulk drug manufacturing facility has been approved by the US FDA.

Albert David, ranked 58th out of 16,000 plus pharma companies, is a part of the Kothari Group of companies. "We manufacture and market a wide range of formulations, large volume parentals and medical disposables. We would concentrate of the formulations market," informed Mundhra.

Some of the company's products are regularly exported to different countries including the United States and Europe. At present, the company operates in major therapeutic segments like analgesics, herbal drugs, anti-bacterials, nutrition, anti-ulcerants, neurotropics, placental extracts, anxiolytics, small and large volume parentals, dermatologicals and disposable syringes and needles. Albert David is a leader in human placental extract therapy. The new facility, which is likely to commence its operations by 2002, is to manufacture oral liquids, tablets, ointments and some bulk drugs.

"The aim is to increase the present production and launch more and more new products every year and with a strong R&D team we hope to achieve this," Mundhra added. The company is in the advanced stages of negotiations with several foreign pharmaceutical companies and multi-nations for technical and licensing tie-ups. Mundhra declined to divulge the details at this stage.
Albert David to set up facility to manufacture oral solids and liquids, Pharma Pulse dated 12.8.2004

CITY - BASED pharmaceutical company Albert David Limited, established more than seven decades ago, is planning to set up a new state-of-the-art manufacturing facility on the outskirts of the city as a part of its modernization and up gradation plans. Currently, the company manufactures and markers a wide range of pharmaceutical finished dosage form for different therapeutic segments, medical disposables and a wide-range of IV fluids.

Confirming the development, Kamal Prasad Mundhra, executive director of Albert David Limited told Express Pharma Pulse, “The company has decided on principle to set up a state-of-the-art manufacturing facility in and around the city”. “We are already scouting for proper land to set up this new manufacturing facility, which will adhere to all the international specifications like Cgmp, WHO & FDA norms, “he informed. “We will be soon zeroing on the land and the construction will commence immediately. The new facility to be set up at a cost of Rs. 40 crore, is likely to come up in the next two years time, “Mundhra added. “The new facility is likely to manufacture oral solids and liquids, ointments and some bulk drugs. The state-of-the-art manufacturing facility will help us to substantially bring down the per unit cost of production of medicine”, he said.

The company has also decided to upgrade its R&D has also decided to upgrade its R&D facilities. The new R&D facility will e housed in the proposed manufacturing unit. Albert David Limited, is a part of the GD Kothari Group of companies having diverse interests in textiles, engineering items, tea plantations, chemicals, salt processing and international trading. The company’s turnover stood at Rs. 115 crore in the last financial year (2003-04). The company exports its products to countries in Europe, Africa and in the US. At present, the company is operating in major therapeutic segments like NS-AIDs, herbal drugs, anti-bacterials, anti-ulcerants, neurotropics, anxiolytics, small and large volume parentals, dermatological products and disposable syringes and needles. The company is a leader in human placental extract therapy. Placentrex, one of the largest-selling products of the company is celebrating its ‘golden jubilee’ this year :

In a related development, the company has also decided to increase the production capacity of its Ghaziabad factory in Uttar Pradesh producing a wide range of IV fluids.

Fax - +91(033) 2225-8714; 2212-9629
E-Mail - adidavid@dataone.in, adidavid@cal.vsnl.net.in, adlho@adlindia.in